Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Manuel A Sanchez-GarciaInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0003-3914-2332
Nieves Lara-UreñaInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0001-6390-1672
Rosana March-DiazInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0002-7320-451X
Clara Ortega-de San LuisInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0002-8365-2762
Silvia Quiñones-CañeteInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0009-0006-8631-7536
Bella Mora-RomeroInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.
Juan M Barba-ReyesDepartamento de Neurociencias. Unidad de Biología Celular. Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA). Universidad de Cádiz, Cadiz, Spain.
Daniel Cabello-RiveraInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0001-7628-0000
Carmen Romero-MolinaInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0002-3119-961X
Antonio Heras-GarvinInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0003-2231-2681
Victoria NavarroInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0002-4385-9697
Jose Lopez-BarneoInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0003-4101-6095
Marisa VizueteInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0001-5114-9428
Javier VitoricaInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0002-0641-7902
Ana M Muñoz-CabelloInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0002-8047-768X
Ana B Muñoz-ManchadoDepartamento de Neurociencias. Unidad de Biología Celular. Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA). Universidad de Cádiz, Cadiz, Spain.
Matthew E CokmanHypoxia Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-3310-4821
Alicia E Rosales-NievesInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0001-9119-1604
Alberto PascualInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0001-5459-6207
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Microglia respond to Alzheimer's disease (AD) with varied transcriptional responses. We show that oligomeric Aß (oAß) induces the expression of
Indexed as
Alzheimer DiseaseForkhead Box Protein O3Hypoxia-Inducible Factor-Proline DioxygenasesInterferon Type IMicrogliaAmyloid beta-PeptidesAnimalsDisease Models, AnimalDisease ProgressionHumansMiceSignal TransductionAmyloid beta-PeptidesForkhead Box Protein O3FoxO3 protein, mouseHypoxia-Inducible Factor-Proline DioxygenasesInterferon Type I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Inactivation of the PHD3-FOXO3 axis blunts the type I interferon response in microglia and ameliorates Alzheimer's disease progression. · full record | OpenQuestion